394.54MMarket Cap-1.01P/E (TTM)
6.210High5.750Low1.24MVolume6.000Open5.620Pre Close7.36MTurnover2.22%Turnover RatioLossP/E (Static)68.38MShares19.71052wk High-2.11P/B321.20MFloat Cap5.21052wk Low--Dividend TTM55.67MShs Float64.540Historical High--Div YieldTTM8.19%Amplitude5.210Historical Low5.955Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
No comment yet